Factors associated with antidepressant, anxiolytic, and other psychotropic medication use to treat psychiatric symptoms in the city of São Paulo, Brazil

Date
2014-05-01Author
Blay, Sergio L. [UNIFESP]
Fillenbaum, Gerda G.
Pitta, Jose C. [UNIFESP]
Peluso, Erica T.
Type
ArtigoISSN
0268-1315Is part of
International Clinical PsychopharmacologyDOI
10.1097/YIC.0000000000000008Metadata
Show full item recordAbstract
The objective of this study was to examine the prevalence and characteristics of adult psychotropic medication use in São Paulo, Brazil. Information on lifetime and 12-month psychotropic medication use, and psychiatric status was obtained from a representative sample of 2000 adults aged 18-65 years in São Paulo, Brazil. Lifetime and 12-month use of psychotropic medications was 16.8 and 7.1%, respectively. of the 22.8% of patients with current psychiatric problems, 29.5% reported lifetime use and 15.8% (5.6% of the sample) reported 12-month use (anxiolytics: 2.7%, antidepressants: 1.8%, alternative medicines: 0.9%, antipsychotics: 0.4%, mood stabilizers: 0.4%, hypnotics: 0.3%; multiple class use occurred). the most frequent prescribers were psychiatrists and general practitioners. Determinants of use included identification as a psychiatric case (four-fold increased odds), being female (three-fold increase), age (4-5% per additional year), and lower odds if married. Education, employment status, and birth in São Paulo were not associated with use. Income did not affect anxiolytic use, but antidepressant and alternative medicine use was associated with higher income. These results show that psychotropic drug use was comparatively low. Only 15.8% of patients with psychiatric problems reported recent psychotropic use. Comparable with other studies, use was greater among women and increased with age.
Citation
International Clinical Psychopharmacology. Philadelphia: Lippincott Williams & Wilkins, v. 29, n. 3, p. 157-165, 2014.Keywords
middle-income countrypsychiatric problems
antidepressants
pharmacoepidemiology
depression
anxiolytics
Brazil
psychotropic drugs
Sponsorship
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Bolsista de Produtividade em Pesquisa
National Institute on Aging
Collections
- EPM - Artigos [17709]